Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,917.20
(
-0.14%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
90.68
(
-2.14%
)
Bitcoin
76,022.18
(
2.92%
)
News Focus
News Focus

Replies to post #819394 on NorthWest Biotherapeutics Inc (NWBO)

Replies to #819394 on NorthWest Biotherapeutics Inc (NWBO)
icon url

SkyLimit2022

03/26/26 11:43 AM

#819395 RE: Investor082 #819394

zero82,

Thanks for your insights about “big pharma” 😶

Both DCVax®-L & the polarized aDC1 platform are included in active PII combo trials with
Merck’s pembrolizmab & participants in those trials are being treated TODAY.

The forthcoming COMBO trial for ovarian cancer involves the polarized aDC1 platform too…

The NIH database entry for Dr. Kalinski’s previous grant award may provide insight into the potential design of the ovarian cancer combo trial:

🇺🇸U.S. National Institutes of Health Grants Database



Perhaps even more valuable than the funding itself, the validation that comes with a rigorously peer-reviewed grant award is immensely significant!



Dr. Kalinski




University of Pittsburgh Hillman Cancer Center



The polarized aDC1 platform has also been studied in breast cancer with promising results…

The Dava Oncology Breast Cancer Summit was a noteworthy event last August—deserved more attention. NWBO’s polarized aDC1 platform technology was featured, & combo with checkpoint blockade was highlighted!

Dr. Shipra Gandhi was the principal on the aDC1 combo trial NCT04348747 before joining the Winship Cancer Institute at Emory University. Dr. Sheheryar Kabraji is the current principal of the study, & he also attended the conference.







ASCO 2025 Abstract
Bullish
Bullish